Effects of spironolactone-altizide on left ventricular hypertrophy

Acta Cardiologica

Volumn 53, Issue 5, 1998, Pages 261-267

  Degre, Serge ^a   Detry, Jean Marie ^b   Unger, Philippe ^a   Cosyns, Jacques ^b   Brohet, Christian ^b   Kormoss, Nicolas ^c  

^a ERASME HOSPITAL   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Searle Continental Pharma Inc   (Belgium)

Author keywords

Altizide; Hypertension; Left ventricular hypertrophy; Spironolactone

Indexed keywords

ALDACTAZINE; POTASSIUM SPARING DIURETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE SEPTUM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE ANTAGONISTS; BENZOTHIADIAZINES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SODIUM CHLORIDE SYMPORTER INHIBITORS; SPIRONOLACTONE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0032434524     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Levy D., Garrison RH., Savage DD. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322: 1561-1566.
2. Frohlich ED. Left ventricular hypertrophy: further evidence of risk. J Am Coll Cardiol 1991; 15: 1295-1296.
3. Casale PN, Devereux RB, Milner M. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-178.
4. Koren MJ, Devereux RB, Casale PN. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
5. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertension patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
6. Sen S, Tarazi RC, Bumpus FM. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res 1977; 11: 427-433.
7. Bauwens FR, Duprez DA, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J., Vermeulen A., Clement DL. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1991; 68: 925-929.
8. Devereux RB, Reichek N. Echocardiographic determination of LVM in man: anatomic validation of the method. Circulation 1977; 55: 613-618.
9. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1996; 57: 450-458.
10. Fagard RH. Reversibility of left ventricular hypertrophy by antihypertensive drugs. Netherlands Journal of Medicine 1995; 47: 173-179.
11. Dahlof B, Pennert K, Hansson L. Regression of left ventricular hypertrophy - A meta analysis. Clin and Exper Hyper-Theory and Practice 1992; A14: 173-180.
12. Neaton JD, Grimm RH JR, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R. Treatment of Mild Hypertension Study (TOMHS). JAMA 1993; 270: 713-724.
13. Gottdiener JS, Reda DJ, Massic BM, Materson BJ, Williams DW, Anderson RJ. Effects of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 1997; 95: 2007-2010.
14. Balansard P, Poggi JN, Baralla A, Frances Y, Gonzalez T, Aidibe A, Raufast D, Malaterre H, Ferracci A. Paramètres de masse cardiaque, de relaxation ventriculaire et leurs corrélations avec la pression artérielle enregistrée au repos et en ambulatoire. Arch Mal Coeur 1991; 84: 1029-1031.
15. Lombes M, Alfaidy N, Farman N, Bonvalet JP. Human-transplanted heart expresses both the mineralocorticoid receptor and the 11 β-hydroxysteroid dehydrogenase. (Abstract) Eur Heart J 1994; 15 suppl 206: 1150.
16. Lombes M, Rafestin-Oblin ME, Gasc JM, Farman N, Bonvalet JP. Immunohisto-chemical and biochemical characterisation of mineralocorticoid receptors in the cardiovascular system. Colloque INSERM, John Libbey Eurotext Ltd Paris-Londres 1991; 215: 237.
17. Weber KT, Brilla CG. Myocardial fibrosis, aldosterone, and antialdosterone therapy: evolving concepts in the management of congestive heart hailure. G.D. Searle & Co. U.S.A. 1991; 8: 1-10.
18. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
19. Klug D, Robert V, Swynghedauw B. Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol 1993; 71: 46A-54A.
20. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage duration product. J Am Coll Cardiol 1992; 20: 1180-1186.
21. Vacek JL, Wilson DB, Botteron GW, Dobbins J. Techniques for the determination of left ventricular mass by signal-averaged electrocardiography. Am Heart J 1990; 120: 958-963.
22. Okin PM, Roman MJ, Devereux RB, Borer JS, Kligfield P. Electrocardiographic diagnosis of left ventricular hypertrophy by the time-voltage integral of the QRS. J Am Coll Cardiol 1994; 23: 133-140.
23. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995; 25: 417-423.